DDInter1729 DDInter1004
Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) of the arylalkanoic acid class that is marketed by Merck under the brand name Clinoril. Like other NSAIDs, it may be used in the treatment of acute or chronic inflammatory conditions. Sulindac is a prodrug, derived from sulfinylindene, that is converted _in vivo_ to an active sulfide compound by liver enzymes. There is evidence from some studies that sulindac may be associated with fewer gastrointestinal side effects than other NSAIDs, except for the cyclooxygenase-2 (COX-2) inhibitor drug class. This may be due to the sulfide metabolite undergoing enterohepatic circulation thus maintaining constant blood levels of the compound without inducing gastrointestinal effects, where the drug is excreted in the bile and then reabsorbed from the intestines. While its full mechanism of action is not fully understood, sulindac
Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate.
Sulindac {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Kanamycin
Sulindac {u} (Compound) causes {v} (Side Effect) Paraesthesia
Paraesthesia {u} (Side Effect) is caused by {v} (Compound) Kanamycin
Sulindac {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) regulates {v} (Gene) GDF15
GDF15 {u} (Gene) is downregulated by {v} (Compound) Kanamycin
Sulindac {u} (Compound) causes {v} (Side Effect) Paraesthesia
Paraesthesia {u} (Side Effect) is caused by {v} (Compound) Tobramycin
Tobramycin {u} (Compound) resembles {v} (Compound) Kanamycin
Sulindac {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Lidocaine
Lidocaine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Kanamycin
Sulindac {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Digoxin
Digoxin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Kanamycin
Sulindac {u} (Compound) causes {v} (Side Effect) Paraesthesia
Paraesthesia {u} (Side Effect) is caused by {v} (Compound) Amikacin
Amikacin {u} (Compound) resembles {v} (Compound) Kanamycin
Sulindac {u} (Compound) causes {v} (Side Effect) Tinnitus
Tinnitus {u} (Side Effect) is caused by {v} (Compound) Nadolol
Nadolol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Kanamycin
Sulindac {u} (Compound) causes {v} (Side Effect) Vertigo
Vertigo {u} (Side Effect) is caused by {v} (Compound) Indomethacin
Indomethacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Kanamycin
Sulindac {u} (Compound) binds {v} (Gene) PTGDR2
PTGDR2 {u} (Gene) is bound by {v} (Compound) Indomethacin
Indomethacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Kanamycin
Sulindac (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Kanamycin (Compound)
Sulindac (Compound) causes Paraesthesia (Side Effect) and Paraesthesia (Side Effect) is caused by Kanamycin (Compound)
Sulindac (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) regulates GDF15 (Gene) and GDF15 (Gene) is downregulated by Kanamycin (Compound)
Sulindac (Compound) causes Paraesthesia (Side Effect) and Paraesthesia (Side Effect) is caused by Tobramycin (Compound) and Tobramycin (Compound) resembles Kanamycin (Compound)
Sulindac (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Lidocaine (Compound) and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Kanamycin
Sulindac (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Digoxin (Compound) and Digoxin may cause a minor interaction that can limit clinical effects when taken with Kanamycin
Sulindac (Compound) causes Paraesthesia (Side Effect) and Paraesthesia (Side Effect) is caused by Amikacin (Compound) and Amikacin (Compound) resembles Kanamycin (Compound)
Sulindac (Compound) causes Tinnitus (Side Effect) and Tinnitus (Side Effect) is caused by Nadolol (Compound) and Nadolol may cause a minor interaction that can limit clinical effects when taken with Kanamycin
Sulindac (Compound) causes Vertigo (Side Effect) and Vertigo (Side Effect) is caused by Indomethacin (Compound) and Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin
Sulindac (Compound) binds PTGDR2 (Gene) and PTGDR2 (Gene) is bound by Indomethacin (Compound) and Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin